- Home
- BG vs INCY Comparison
BG vs INCY Comparison
Compare BG & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BG
- INCY
- Stock Information
- Founded
- BG 1818
- INCY 1991
- Country
- BG United States
- INCY United States
- Employees
- BG N/A
- INCY N/A
- Industry
- BG Packaged Foods
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- BG Consumer Staples
- INCY Health Care
- Exchange
- BG Nasdaq
- INCY Nasdaq
- Market Cap
- BG 12.2B
- INCY 13.3B
- IPO Year
- BG N/A
- INCY 1993
- Fundamental
- Price
- BG $78.66
- INCY $73.47
- Analyst Decision
- BG Buy
- INCY Buy
- Analyst Count
- BG 7
- INCY 19
- Target Price
- BG $115.14
- INCY $75.44
- AVG Volume (30 Days)
- BG 1.6M
- INCY 1.6M
- Earning Date
- BG 02-05-2025
- INCY 02-10-2025
- Dividend Yield
- BG 3.47%
- INCY N/A
- EPS Growth
- BG N/A
- INCY N/A
- EPS
- BG 7.96
- INCY 0.15
- Revenue
- BG $54,502,000,000.00
- INCY $4,075,860,000.00
- Revenue This Year
- BG N/A
- INCY $16.00
- Revenue Next Year
- BG $2.08
- INCY $10.47
- P/E Ratio
- BG $9.88
- INCY $494.37
- Revenue Growth
- BG N/A
- INCY 12.94
- 52 Week Low
- BG $75.75
- INCY $50.35
- 52 Week High
- BG $114.92
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- BG 41.43
- INCY 57.44
- Support Level
- BG $78.60
- INCY $71.72
- Resistance Level
- BG $82.57
- INCY $73.83
- Average True Range (ATR)
- BG 1.82
- INCY 1.85
- MACD
- BG 0.43
- INCY 0.37
- Stochastic Oscillator
- BG 42.67
- INCY 78.61
About BG Bunge Limited
Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes, and corn-based products in North and South America.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.